An Observational Longitudinal Post-authorization Safety Study of STELARA® in the Treatment of Psoriasis and Psoriatic Arthritis: Analysis of Major Adverse Cardiovascular Events (MACE) using Swedish National Health Registers (QUANTIFY STELARA MACE) First published 07/02/2023 Last updated 23/04/2024 EU PAS number:EUPAS49873 Study Finalised